| Amount | Holding |
|---|---|
| 4.39% | Eli Lilly and Co |
| 3.47% | Biogen Inc |
| 3.08% | Seattle Genetics Inc |
| 2.94% | Alibaba Group Holding Ltd ADR |
| 2.62% | Amgen Inc |
| 2.47% | Abiomed Inc |
| 2.44% | Micron Technology Inc |
| 2.17% | Insulet Corp |
| 2.17% | Splunk Inc |
| 2.00% | AstraZeneca PLC ADR |
Expense Ratio Rating
9 /10
Expense Rating
4 /10
Market Score
9 /10
Category Score
8 /10
Market Size
9 /10
Expenses: 0.64% (Better than 1% of similar funds)
This is an OK choice for a Large Growth US Stocks fund. See why ยป
| Amount | Holding |
|---|---|
| 4.39% | Eli Lilly and Co |
| 3.47% | Biogen Inc |
| 3.08% | Seattle Genetics Inc |
| 2.94% | Alibaba Group Holding Ltd ADR |
| 2.62% | Amgen Inc |
| 2.47% | Abiomed Inc |
| 2.44% | Micron Technology Inc |
| 2.17% | Insulet Corp |
| 2.17% | Splunk Inc |
| 2.00% | AstraZeneca PLC ADR |
Minafi - The intersection of FI, minimalism & mindfulness.
Don't miss out on new posts, courses, interactive articles and more!
Join & Get Your First Course Free© 2025 Adam Fortuna
Site Map